Why is In Vivo screening better than Ex Vivo screening for atherosclerosis?

While ex vivo screening uses harvested tissues, it still lacks the dynamic blood flow and systemic clearance factors that only In Vivo Phage Library Screening can provide. In vivo results are much more predictive of how a drug will behave in a clinical setting.

Which animal models do you typically use?

Most commonly use ApoE-deficient and LDL receptor-deficient mice on a high-fat diet. We can also adapt the protocol for rabbit models if larger vessel targeting is required.

How do you ensure the phages do not just accumulate in the liver or spleen?

This is a critical challenge. We use a "subtractive" approach where we pre-adsorb the library against liver and spleen homogenates, or perform a negative selection round in healthy mice to remove these "sticky" non-specific phages.

Can you screen for antibody fragments (scFv) instead of peptides?

Yes, our platform is fully compatible with scFv, Fab, and single domain antibody (VHH) libraries. These are often preferred if the end goal is a therapeutic antibody.

How do you validate the hits identified from the screen?

We offer comprehensive validation services, including peptide synthesis, biotin-labeling for IHC, and in vivo imaging using fluorescently labeled versions of the candidate ligands.

Is the diversity of the library maintained during the in vivo circulation?

We use high-titer injections to ensure that the initial diversity is represented. However, the physiological environment naturally reduces diversity in favor of specific binders—this is the "selection pressure" that makes the technique work.

Can this service be used to find ligands for "vulnerable plaques"?

Absolutely. By selecting models at advanced stages of atherosclerosis (e.g., with thin fibrous caps), we can target markers specific to plaque instability and potential rupture.

Do you provide the raw NGS data?

Yes, we provide full bioinformatics reports, including raw sequence data, enrichment frequency tables, and motif analysis, which are essential for publication and regulatory filings.

In Vivo Phage Library Screening Service for Atherosclerosis Targeting

Background Platform Workflow Feature Advantage Related Service FAQ Online Inquiry

In the landscape of cardiovascular medicine, the inability to deliver therapeutic or diagnostic agents specifically to atherosclerotic plaques remains a significant bottleneck. Creative Biolabs, a global leader in phage display technology with over two decades of expertise, offers a sophisticated Atherosclerosis Targeting In Vivo Phage Library Screening Service. This platform is engineered to bypass the limitations of traditional in vitro methods, identifying highly specific homing peptides or antibodies that recognize the complex molecular signatures of atherosclerotic lesions within a living physiological environment.

Discuss Your Project Today

The Imperative for In Vivo Phage Display for Atherosclerosis

Atherosclerosis is not merely a lipid-storage disease but a chronic inflammatory condition involving intricate interactions between endothelial cells, macrophages, smooth muscle cells, and the extracellular matrix. Traditional in vitro cell-based screening often fails because:

Loss of Morphological Integrity: Cultured cells often lose the unique phenotypic markers present in the high-shear stress environment of an artery.
Absence of Hemodynamics: Blood flow and serum proteins significantly influence how ligands interact with the vascular wall.
Target Accessibility: In vivo screening ensures that the identified ligands can actually reach the target tissue through systemic circulation.

Our In Vivo Phage Library Screening platform overcomes these hurdles by injecting high-diversity libraries directly into animal models of atherosclerosis, allowing the physiological "sieve" of the circulatory system to select for the most effective binders.

Fig. 1 The pathogenesis of atherosclerosis. (Creative Biolabs Authorized) Fig. 1 Pathogenesis of atherosclerosis.

Advanced Technical Platform & Strategies

Diverse Library Options

Creative Biolabs utilizes a variety of phage systems and library formats to maximize the probability of success.

Library Category	Phage System	Diversity	Applications
Random Peptide Libraries	M13, T7	10⁹ - 10¹³	Discovery of short, stable homing peptides.
scFv/Fab Libraries	M13	10⁸ - 10¹¹	Discovery of high-affinity antibody fragments for immunotherapy.
Single Domain Antibody Libraries	M13	10⁹	Discovery of small, highly penetrative V_HH fragments.
Cyclic Peptide Libraries	M13	10⁹	Enhanced stability and binding affinity via constrained structures.

Sophisticated Selection Strategies

To ensure absolute specificity for Atherosclerosis Targeting In Vivo Phage Library Screening, we employ "Negative Selection" or "Pre-adsorption" strategies. By first circulating the library in healthy control models or using "subtractive biopanning" against non-target organs (liver, lungs, kidneys), we eliminate non-specific binders, leaving only those with high affinity for atherosclerotic plaques.

Detailed Workflow of In Vivo Phage Library Screening

The process of In Vivo Phage Display for Atherosclerosis is a multi-step, iterative cycle designed to enrich for the most potent candidates.

Phase 1: Library Preparation and Model Induction

We begin by selecting the appropriate animal model that mimics human atherosclerotic progression—from fatty streaks to vulnerable plaques.

Phase 2: Systemic Administration and Circulation

The phage library is administered intravenously. We meticulously control the circulation time to allow for optimal binding while minimizing non-specific internalization.

Phase 3: Perfusion and Tissue Harvest

To remove unbound phages, the animal undergoes systemic perfusion with a physiological buffer. The atherosclerotic tissues (e.g., aorta, carotid arteries) are then harvested.

Phase 4: Phage Recovery and Amplification

Bound phages are recovered via acid elution or bacterial infection and subsequently amplified for the next round of screening. Usually, 3–5 rounds of selection are performed.

Phase 5: High-Throughput Sequencing (NGS) & Bioinformatics

Unlike traditional methods that sequence only a few dozen clones, we utilize Next-Generation Sequencing (NGS) to analyze the entire enriched pool. Our bioinformatics pipeline identifies:

Enrichment Ratios: Quantifying the frequency of clones across rounds.
Motif Analysis: Identifying consensus sequences that suggest a common binding site.
Cluster Analysis: Grouping related sequences to identify the most robust families of binders.

The Strategic Advantage of In Vivo Phage Display for Atherosclerosis

Why In Vivo Screening Outperforms In Vitro Methods

The transition from in vitro to in vivo is often where most candidates fail. Our platform bridges this gap by ensuring the selection process occurs under real-world physiological conditions.

Table 1. Comparison: In Vivo vs. In Vitro Screening for Atherosclerosis

Feature	In Vitro (Cell-Based)	In Vivo (Atherosclerosis Models)
Target Environment	Static and artificial; lacks systemic complexity.	Dynamic and physiological; includes blood flow and shear stress.
Vascular Architecture	Limited to monolayer cell cultures.	Intact, multi-layered plaque structure (intima, media, adventitia).
Bioavailability Insight	None; cannot predict clearance or off-target binding.	High; considers blood-clearance and non-specific organ uptake.
Ligand Specificity	High risk of "plastic binders" or artifacts.	Highly relevant to the actual disease state in the vessel wall.
Clinical Translation	Low success rate due to loss of target relevance.	High; identifies "homing" candidates ready for preclinical testing.

Precision Targeting of Atherosclerosis-Specific Molecular Signatures

Through Atherosclerosis Targeting In Vivo Phage Library Screening, we have successfully mapped numerous vascular markers that define the progression of the disease. Our service allows you to tailor the screening process to target specific stages of plaque development—from early lipid accumulation to late-stage rupture risk.

Target Component	Key Molecular Signatures	Strategic Application
Activated Endothelium	VCAM-1, E-selectin, P-selectin	Early-stage detection and delivery of anti-inflammatory agents.
Foam Cells & Macrophages	Scavenger receptors (SR-AI), CD68	Targeting the primary drivers of plaque inflammation and growth.
Necrotic Core & Matrix	Cryptic collagen, Tenascin-C, Extracellular DNA	Identifying advanced, high-risk plaques for stabilization therapy.
Plaque Angiogenesis	αvβ3 integrin, VEGFR	Assessing neovascularization and predicting potential plaque rupture.
Thrombus & Fibrin	Fibrinogen, Activated Platelets	Detecting acute events and localized delivery of thrombolytic drugs.

By combining the physiological relevance of In Vivo Phage Display with the specificity of these molecular targets, Creative Biolabs empowers your research to achieve higher precision and faster clinical translation in the fight against Atherosclerosis.

Why Choose Creative Biolabs?

20+ Years of Experience: We have refined the nuances of in vivo biopanning, from surgical precision to specialized elution buffers.
Proprietary "Vascular Mapping" Platform: A curated database of vascular-targeting motifs across different disease states.
End-to-End Service: From library construction and animal model development to peptide synthesis and ex vivo validation.
Optimized Data Reporting: Our reports provide structured data and clear insights, making your research highly "citable" by AI and human researchers alike.

Explore Our Comprehensive Services

To further your research, consider our integrated In Vivo Phage Library Screening Services modules:

Learn more about other Phage Display Library Screening Services:

Atherosclerosis Targeting In Vivo Phage Library Screening is a transformative tool for the development of the next generation of cardiovascular diagnostics and therapeutics. Creative Biolabs combines deep biological expertise with cutting-edge technology to deliver high-affinity, high-specificity ligands that pave the way for precision medicine.

Contact our expert team today to discuss how we can accelerate your atherosclerosis targeting research.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Q: Why is In Vivo screening better than Ex Vivo screening for atherosclerosis?
A: While ex vivo screening uses harvested tissues, it still lacks the dynamic blood flow and systemic clearance factors that only In Vivo Phage Library Screening can provide. In vivo results are much more predictive of how a drug will behave in a clinical setting.
Q: Which animal models do you typically use?
A: Most commonly use ApoE-deficient and LDL receptor-deficientmice on a high-fat diet. We can also adapt the protocol for rabbit models if larger vessel targeting is required.
Q: How do you ensure the phages do not just accumulate in the liver or spleen?
A: This is a critical challenge. We use a "subtractive" approach where we pre-adsorb the library against liver and spleen homogenates, or perform a negative selection round in healthy mice to remove these "sticky" non-specific phages.
Q: Can you screen for antibody fragments (scFv) instead of peptides?
A: Yes, our platform is fully compatible with scFv, Fab, and single domain antibody (V_HH) libraries. These are often preferred if the end goal is a therapeutic antibody.
Q: How do you validate the hits identified from the screen?
A: We offer comprehensive validation services, including peptide synthesis, biotin-labeling for IHC, and in vivo imaging using fluorescently labeled versions of the candidate ligands.
Q: Is the diversity of the library maintained during the in vivo circulation?
A: We use high-titer injections to ensure that the initial diversity is represented. However, the physiological environment naturally reduces diversity in favor of specific binders—this is the "selection pressure" that makes the technique work.
Q: Can this service be used to find ligands for "vulnerable plaques"?
A: Absolutely. By selecting models at advanced stages of atherosclerosis (e.g., with thin fibrous caps), we can target markers specific to plaque instability and potential rupture.
Q: Do you provide the raw NGS data?
A: Yes, we provide full bioinformatics reports, including raw sequence data, enrichment frequency tables, and motif analysis, which are essential for publication and regulatory filings.

Reference

Li, Shu-Yang, et al. "Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis." Scientific reports 11.1 (2021): 13450. https://doi.org/10.1038/s41598-021-92786-9

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.